WASHINGTON, Jan. 6, 2026 – The U.S. Food and Drug Administration approved a new formulation of mosunetuzumab-axgb (Lunsumio VELO™) to treat advanced forms of follicular lymphoma. The new formulation is given as a one-minute injection, while the previously approved infusion formulation takes up to four hours.
“This is a big step forward for people with follicular lymphoma. Not only does this injection take just one minute, but it can be administered in the oncologist’s office, so patients won’t have to travel to specialized centers for an hours-long infusion,” says Lore Gruenbaum, Ph.D., Chief Scientific Officer of Blood Cancer United.
People with follicular lymphoma are living longer than ever, but that also means they are dealing with lifelong disease management, and advances like this one can make a big difference in the quality of life of patients and their families says Dr. Gruenbaum.
Mosunetuzumab is approved for use in adults whose follicular lymphoma has returned or worsened after at least two previous treatments. In a clinical trial, 75% of patients had their disease respond to treatment, including a complete response in nearly six in 10 patients. The median duration of the response was more than 22 months.
Blood Cancer United is working toward a follicular lymphoma cure, including through a $20 million strategic partnership that is connecting researchers worldwide and creating stronger scientific communities to accelerate success.
If you or a loved one need personalized disease, treatment or support information, you can contact one of our Information Specialists: https://bloodcancerunited.org/resources/patients/information-specialists